Barclays
SGMT icon

Barclays’s Sagimet Biosciences SGMT Stock Holding History

Barclays’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Sell
27,429
-1,909
-7% -$10.6K ﹤0.01% 3870
2025
Q4 		$174K Buy
29,338
+22,929
+358% +$165K ﹤0.01% 4396
2025
Q3 		$44K Buy
+6,409
New +$52K ﹤0.01% 4797
2025
Q2 		– Sell
-141
Closed -$460 – 5506
2025
Q1 		$460 Sell
141
-71
-33% -$298 ﹤0.01% 5084
2024
Q4 		$954 Sell
212
-57,018
-100% -$289K ﹤0.01% 5138
2024
Q3 		$159K Buy
57,230
+7,178
+14% +$22.1K ﹤0.01% 4412
2024
Q2 		$171K Buy
50,052
+33,710
+206% +$155K ﹤0.01% 3656
2024
Q1 		$88.6K Buy
16,342
+8,760
+116% +$62.9K ﹤0.01% 4475
2023
Q4 		$41.1K Buy
+7,582
New +$35.8K ﹤0.01% 4804

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays's SGMT Position: Q1 2026 in Review

Barclays reduced its Sagimet Biosciences (SGMT) stake by 6.5% in Q1 2026, selling an estimated $10.6K and leaving 27,429 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #3870.

Barclays first reported a position in SGMT in Q4 2023 and has held it in 9 quarters since. The position peaked at $174K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Barclays held 27,429 shares of Sagimet Biosciences worth $143K as of Q1 2026.
  • Barclays sold 1,909 Sagimet Biosciences shares in Q1 2026, an estimated $10.6K.
  • Sagimet Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3870 holding.
  • Barclays first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 9 quarters since.
  • Barclays's Sagimet Biosciences position peaked at $174K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.